Johnson & Johnson’s (NYSE:JNJ) anti-fungal drug Nizoral has been found by regulators in the U.S. and Europe to raise the risk of liver infection and to have dangerous interactions with other medications.
The Food and Drug Administration has determined that Nizoral should not be the first treatment pursued for a fungal infection, as less harmful medicines should be the first line of defense to prevent the risk of liver failure and adrenal problems. The European Medicines Agency has taken things a step further, according to Bloomberg, and recommended a suspension on the marketing of any oral medicines containing ketoconazole, Nizoral’s main ingredient.
Both agencies found that the drug could cause severe liver problems, including liver failure, hepatitis, or other ailments that could lead to necessitating a liver transplant or death. The drug comes in several topical formulas including creams, shampoos, foams, and gels, but only the oral version has been found to lead to liver complications, the FDA said.